Xiaoran Ma
- kawaokashinpei3
- 4月28日
- 読了時間: 2分
更新日：4月30日
Selected journal : Cell
Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient
What is the main question of the paper?
This study investigates whether autologous islets derived from chemically induced pluripotent stem cells (CiPSCs) can safely and effectively restore glycemic control in a patient with type 1 diabetes when transplanted under the abdominal anterior rectus sheath.
How did the anthor address the question?
■Step1
Preparation and quality control of transplanted cells
This part shows how the team turned a patient’s fat cells into working islets. First, they used small-molecule chemicals to reprogram fat cells into CiPSCs. Then, they followed a six-stage process to turn these cells into islets, where about 60% were insulin-producing beta cells. To make sure they were safe, the team checked for harmful mutations using DNA sequencing (WGS/WES) and tested the cells in 244 mice.
■Step2
Strategic transplantation
The team chose a new place for the transplant to solve old problems like acute graft loss. Using ultrasound for guidance, they injected about 1.5 million islet equivalents into the space under the patient's abdominal muscle (the rectus sheath). This site is better than the liver because it avoids the instant blood-mediated inflammatory response that often kills transplanted cells. Because the site is extraperitoneal and stable, it also makes it very easy for the medical team to check the graft's condition using non-invasive tools like ultrasound and MRI.
■Step3
Long-term results and patient recovery
The team monitored the patient's condition for as long as one year. The patient started needing less insulin within two weeks and stopped needing insulin shots completely 75 days after the transplant. The patient's blood sugar levels (HbA1c) dropped from 7.57% to a healthy range of around 5%. Also, the patient's "time-in-target" range improved significantly from a baseline of 43% to over 98% for most of the year. Most importantly, the patient had no dangerous low-blood-sugar events, and regular MRI scans confirmed that the graft stayed stable without any signs of tumor growth.
What is the strength of the paper?
The most significant breakthrough of this study is combining a new cell source with an easy-to-reach transplantation site, which makes cell therapy much safer.
I think the strength of this paper is the choice of the transplantation site and how easy it is to monitor. By placing the islets under the abdominal rectus sheath, the researchers avoided the damage caused by blood contact and created an ideal "monitoring window". This design makes it easy for doctors to check the graft’s shape using standard imaging tools like ultrasound and MRI. It solves the biggest worry in stem cell therapy—potential tumor formation by making the graft's growth transparent and controllable. This provides a practical path for future clinical studies.
Comment
I believe this transplantation is wonderful because the minimally invasive treatment significantly reduces the burden on the patient. I suspect that by minimizing surgical trauma, this procedure keeps the activation of immune system at a low level and leads to the good outcome such as insulin independence.
Comment by Toshifumi Otsuki
